AlphaValue Corporate Services
COVERAGE
ABOUT US
CONTACT
FR
Crossject
ISIN : FR0011716265
Supergenerics
Things are getting going...hopefully
Opinion
Target Price
Upside
Price
Market Cap
Bloomberg Code
Investors Relation
Buy
€ 7.83
234%
€ 2.35
€M 96.8
ALCJ FP
Click here
Access to interactive analysis
Analyst reports
Receive email updates for free
SUBMIT
Date
Title
Research
17/07/2024
We are still believers
Download
05/06/2024
Success of the capital increase
Download
02/05/2024
We welcome the securing of the group’s financial needs
Download
03/04/2024
Patience is a virtue… hopefully
Download
28/02/2024
Securing the financing needs
Download
08/02/2024
No news is not always good news...
Download
06/01/2024
Marketing initiative in the US
Download
03/01/2024
A new distribution agreement in Northern Europe
Download
28/09/2023
H1 23: no surprises before the release of the detailed accounts in October
Download
27/03/2023
No real news in the FY22 results.
Download
23/03/2023
FY22: not much to learn from the release
Download
12/01/2023
Crossject has announced it has raised €14m in debt to finance its expansion.
Download
26/09/2022
Minor changes after H1 22
Download
23/09/2022
A rather reassuring H1 22
Download
05/09/2022
Adjusting our forecasts to the new number of shares
Download
25/07/2022
The update of our assumptions confirms a huge upside potential
Download
22/07/2022
The update of our assumptions confirms a huge upside potential
Download
20/06/2022
A major breakthrough for Crossject
Download
29/03/2022
FY21: not very meaningful, as expected
Download
17/12/2021
New financing
Download
24/09/2021
H1 21: unsurprising (as usual)
Download
31/08/2021
We have fine-tuned our numbers on the back of the FY20 detailed accounts. Forecasts were also partly amended but net results remain low in the next few years which explains why a small change in the e
Download
18/08/2021
We have only integrated the detailed numbers for FY20, which translate into a slightly lower EPS. However, the change is not meaningful given the still very low level of results of the company before
Download
18/06/2021
Another good piece of news for the group
Download
17/06/2021
A licensing agreement for Zeneo Hydrocortisone in the US and Canada
Download
31/03/2021
FY20 unsuprising; waiting for more
Download
15/12/2020
A double bond issue
Download
21/09/2020
Update on the group's business
Download
22/05/2020
No major changes after the release of the FY19 report
Download
29/03/2020
Meaningless FY19 results and product update
Download
23/12/2019
Extra-financing to increase visibility
Download
20/11/2019
A €2.6m non-dilutive issue
Download
15/10/2019
Cooperation agreement with the US Department of Defense
Download
10/09/2019
H1 19: no surprise
Download
10/07/2019
Warrants to existing shareholders
Download
19/06/2019
A commercial success
Download
18/04/2019
The 2018 bonds fully converted
Download
18/03/2019
No major change post FY18 results
Download
15/03/2019
Slowly but surely
Download
04/02/2019
Some extra non-dilutive financing
Download
24/12/2018
Adjustment in the number of shares
Download
21/12/2018
Success of the capital increase
Download
29/11/2018
A €3.9m capital increase before year-end
Download
28/11/2018
A €3.9m capital increase
Download
22/11/2018
Excellent news: production has resumed
Download
23/10/2018
Bond conversion
Download
03/10/2018
The delayed launch of Zeneo implies a lower target price
Download
27/09/2018
H1 18: insignificant; some more time needed to reach the market
Download
05/09/2018
On its way to reaching the market
Download
13/07/2018
A convertible bond and potential options for existing shareholders
Download
17/05/2018
Business update
Download
22/03/2018
On its way to reach the market…
Download
14/02/2018
A convertible bond and options for existing shareholders
Download
03/02/2018
Orphan disease status for Zeneo® Midazolam in the US
Download
11/12/2017
Update on the company’s activities
Download
25/09/2017
H1 17: a new NTE in the pipeline...and further delays
Download
06/04/2017
The capital increase was successful
Download
14/03/2017
New valuation after the ongoing capital increase
Download
13/03/2017
FY16 results - untelling (as expected) and a €4.3m capital increase
Download
24/11/2016
A strategic review… and some adjustments to our forecasts
Download
23/11/2016
A strategic review….and a few questions
Download
20/09/2016
H1 16 results: not very telling as expected
Download
29/08/2016
When apparent threats are also opportunities
Download
25/02/2016
Initiating coverage of Crossject.
Download
Also available on the following platforms